Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: Prostaglandin E2 exerts its effects through four separate G-protein coupled receptors (EP1, EP2, EP3, and EP4). L-798,106 is a highly selective EP3 receptor antagonist with Ki values of 0.3, 916, >5,000, and >5,000 nM at EP3, EP4, EP1, and EP2, respectively. At 0.2 µM, it blocks the EP3 agonist activity of sulprostone on guinea pig vas deferens and trachea.
L-798,106 is supplied as a crystalline solid. A stock solution may be made by dissolving the L-798,106 in the solvent of choice. L-798,106 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of L-798,106 in these solvents is approximately 10 and 20 mg/ml, respectively. L-798,106 is sparingly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.
Coleman, R.A., Smith, W.L., and Narumiya, S. Classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46, 205-229 (1994).
Juteau, H., Gareau, Y., Labelle, M., et al. Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor. Bioorg. Med. Chem. 9, 1977-1984 (2001).
Jones, R.L., Giembycz, M.A., and Woodward, D.F. Prostanoid receptor antagonists: Development strategies and therapeutic applications. Br. J. Pharmacol. 158(1), 104-145 (2009).